艾伯维(ABBV.US)乌帕替尼新适应症申报上市或将成为首个用于治疗白癜风的全身性药物

智通财经02-04

智通财经APP获悉，当地时间2月3日，艾伯维(ABBV.US)宣布，已向美国 FDA 和欧洲 EMA 提交了乌帕替尼(Upadacitinib，RINVOQ®；15 毫克，每日一次)用于治疗成人和青少年非节段型白癜风(NSV)的新适应症申请。若获得批准，乌帕替尼将成为首个可用于治疗白癜风的全身性药物，以期改变白癜风的治疗格局。乌帕替尼是一种选择性 JAK 抑制剂，已在全球范围内获批多项适应症，涵盖...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608733028?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-04 14:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608733028","market":"hk","top_or_hot":-1,"title":"艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，当地时间2月3日，艾伯维(ABBV.US)宣布，已向美国 FDA 和欧洲 EMA 提交了乌帕替尼(Upadacitinib，RINVOQ®；15 毫克，每日一次)用于治疗成人和青少年非节段型白癜风(NSV)的新适应症申请。若获得批准，乌帕替尼将成为首个可用于治疗白癜风的全身性药物，以期改变白癜风的治疗格局。乌帕替尼是一种选择性 JAK 抑制剂，已在全球范围内获批多项适应症，涵盖...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401479.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-04 14:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401479.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，当地时间2月3日，艾伯维(ABBV.US)宣布，已向美国 FDA 和欧洲 EMA 提交了乌帕替尼(Upadacitinib，RINVOQ®；15 毫克，每日一次)用于治疗成人和青少年非节段型白癜风(NSV)的新适应症申请。若获得批准，乌帕替尼将成为首个可用于治疗白癜风的全身性药物，以期改变白癜风的治疗格局。乌帕替尼是一种选择性 JAK 抑制剂，已在全球范围内获批多项适应症，涵盖...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401479.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0114720955.EUR","symbol_name":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401479.html","article_id":"2608733028","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608733028","pubTimestamp":1770187724,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，当地时间2月3日，艾伯维宣布，已向美国 FDA 和欧洲 EMA 提交了乌帕替尼用于治疗成人和青少年非节段型白癜风的新适应症申请。若获得批准，乌帕替尼将成为首个可用于治疗白癜风的全身性药物，以期改变白癜风的治疗格局。此前公布的 Viti-Up 研究结果支持了此次向FDA和EMA提交的监管申请。据悉，乌帕替尼为艾伯维旗下的重磅产品，2024年全球销售额为59.71亿美元，同比增长50.44%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","BK4566":"资本集团","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4559":"巴菲特持仓","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4588":"碎股","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4550":"红杉资本持仓","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","ABBV":"艾伯维公司","LU0122379950.USD":"贝莱德世界健康科学A2","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4581":"高盛持仓","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC"},"translate_title":"AbbVie (ABBV.US) Upatinib's new indication declaration may become the first systemic drug for the treatment of vitiligo","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1.5},"content_text":"智通财经APP获悉，当地时间2月3日，艾伯维(ABBV.US)宣布，已向美国 FDA 和欧洲 EMA 提交了乌帕替尼(Upadacitinib，RINVOQ®；15 毫克，每日一次)用于治疗成人和青少年非节段型白癜风(NSV)的新适应症申请。若获得批准，乌帕替尼将成为首个可用于治疗白癜风的全身性药物，以期改变白癜风的治疗格局。乌帕替尼是一种选择性 JAK 抑制剂，已在全球范围内获批多项适应症，涵盖特应性皮炎、类风湿关节炎、银屑病关节炎、溃疡性结肠炎、克罗恩病、强直性脊柱炎、放射学阴性中轴型脊柱关节炎、巨细胞动脉炎等。白癜风是一种慢性自身免疫性疾病，NSV是最常见的白癜风类型(约占 84% 的患者)，其特征是双侧对称性脱色白斑，即使在长期稳定后也容易出现不可预测的进展。白癜风的治疗主要围绕三个目标：稳定病情、促进色素再生和维持色素再生。目前尚无获批的全身性药物可用于实现白癜风的这些治疗目标。此前公布的 Viti-Up 研究结果支持了此次向FDA和EMA提交的监管申请。研究结果显示，与安慰剂相比，乌帕替尼在第48周达到了共同主要终点 T-VASI 50 和 F-VASI 75。在两项研究中，在关键排序次要终点方面观察到乌帕替尼与安慰剂存在统计学显著差异，包括第48周时的 F-VASI 50。据悉，乌帕替尼为艾伯维旗下的重磅产品，2024年全球销售额为59.71亿美元，同比增长50.44%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608733028","isCrawlerRequest":true}

艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物

精彩评论

艾伯维(ABBV.US)乌帕替尼新适应症申报上市或将成为首个用于治疗白癜风的全身性药物